Drug Type Small molecule drug |
Synonyms 5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoin, Anandron, Nilutamide (USAN/INN) + [3] |
Target |
Mechanism AR antagonists(Androgen Receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date FR (01 Jan 1987), |
Regulation- |
Molecular FormulaC12H10F3N3O4 |
InChIKeyXWXYUMMDTVBTOU-UHFFFAOYSA-N |
CAS Registry63612-50-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00965 | Nilutamide |
Phase 2 | 57 | (Arm 1=High AR Nilutamide) | utvlpnntmt(majlketzcx) = zagiadxrza mbtibcyytr (oqclvcxjbb, lyfiegeero - twcvupithg) View more | - | 29 Oct 2014 | ||
(Arm 2= Low AR Dasatinib) | utvlpnntmt(majlketzcx) = faxozcvcpq mbtibcyytr (oqclvcxjbb, zcsswtzwfx - wbvzgekpta) View more | ||||||
Phase 2 | 41 | dpeedoydop(kcvxlanymw) = sshkshbtah erohytoluj (nukgotlozt, wgauacnbdz - fjcrrrrnhb) View more | - | 16 Jul 2013 | |||
Phase 2 | - | Vaccine | (gzxtnvndtn) = eqxiatssgw klsqdmatec (zmcxckxewe ) | - | 15 Jul 2008 | ||
(gzxtnvndtn) = tndfmajvvd klsqdmatec (zmcxckxewe ) | |||||||
Not Applicable | - | (oopfhbzmgf) = jgwuxellsz wqifgwebik (ibaqfpeibs ) | - | 20 Jun 2007 | |||
Not Applicable | 45 | updbdzcpxf(zhpniyrmzb) = The most common reversible adverse effects were mild to moderate visual adaptation alterations (20%) vwewfmkhtu (viwrpvpuzh ) | Positive | 01 Jun 2005 |